| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11926-007-0025-Y |
| P698 | PubMed publication ID | 17437671 |
| P50 | author | John P. Bilezikian | Q76765988 |
| P2093 | author name string | Luigi Gennari | |
| P2860 | cites work | Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study | Q32087313 |
| Osteoporosis in men. | Q33752465 | ||
| Genetics of osteoporosis | Q33799831 | ||
| Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites | Q34366766 | ||
| Genetics of male osteoporosis | Q34454731 | ||
| Histomorphometric approach of bone loss in men. | Q34454746 | ||
| Clinical review 144: Estrogen and the male skeleton | Q34587203 | ||
| Epidemiology and outcomes of osteoporotic fractures | Q34671295 | ||
| Treatment of osteoporosis in men. | Q35895418 | ||
| Aromatase activity and bone homeostasis in men. | Q35973043 | ||
| Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. | Q36071882 | ||
| Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis | Q36417304 | ||
| Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials | Q36486895 | ||
| Bone quality--the material and structural basis of bone strength and fragility | Q36488553 | ||
| Bone fragility in men--where are we? | Q36560251 | ||
| Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens | Q37372883 | ||
| Mortality after all major types of osteoporotic fracture in men and women: an observational study. | Q39490012 | ||
| Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study* | Q41140274 | ||
| Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. | Q42169651 | ||
| Osteoblast dysfunction in male idiopathic osteoporosis | Q42490644 | ||
| Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. | Q43705600 | ||
| Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study | Q43794535 | ||
| Prevalence of low femoral bone density in older U.S. adults from NHANES III. | Q44113237 | ||
| Reversal of bone loss in mice by nongenotropic signaling of sex steroids | Q44193903 | ||
| Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. | Q44645555 | ||
| A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. | Q44924325 | ||
| Estrogens are essential for male pubertal periosteal bone expansion | Q45173609 | ||
| BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. | Q46029353 | ||
| Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. | Q46433506 | ||
| Factors associated with the lumbar spine and proximal femur bone mineral density in older men. | Q46464403 | ||
| LRP5 gene polymorphisms and idiopathic osteoporosis in men. | Q46708165 | ||
| Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. | Q46861764 | ||
| Testosterone and estradiol among older men. | Q46861767 | ||
| Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. | Q47334216 | ||
| Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. | Q47855974 | ||
| Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density | Q47856481 | ||
| Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy | Q49133803 | ||
| Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. | Q51075373 | ||
| Official positions of the international society for clinical densitometry. | Q53286711 | ||
| The near absence of osteoporosis treatment in older men with fractures | Q57450305 | ||
| Alendronate for the Treatment of Osteoporosis in Men | Q57450326 | ||
| Osteoporosis in young men: a syndrome of hypercalciuria and accelerated bone turnover | Q58086500 | ||
| Risk factors for spinal osteoporosis in men | Q71123827 | ||
| Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells | Q71687663 | ||
| Idiopathic osteoporosis--is the osteoblast to blame? | Q73668253 | ||
| Insulin-like growth factor-I in men with idiopathic osteoporosis | Q73668258 | ||
| The endocrinology of aging | Q73797354 | ||
| Undertreatment of osteoporosis in men with hip fracture | Q78401423 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 71-77 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Osteoporosis in men: pathophysiology and treatment | |
| P478 | volume | 9 |
| Q43485164 | Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study |
| Q42919298 | Associations between amino acids and bone mineral density in men with idiopathic osteoporosis |
| Q37134718 | Causes, consequences, and treatment of osteoporosis in men. |
| Q37062092 | Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects |
Search more.